Opioid Manufacturers Should Prepare For A Tobacco Moment
US Senate Democrats are eager to bring in prescription opioid manufacturer executives for a hearing that would recreate the famous image of tobacco industry CEOs being sworn in by Congress. That moment probably won’t come this year – but may be inevitable before the opioid abuse crisis can be declared over.
You may also be interested in...
US Medicare And Opioids: Inspector General Sees Improvement
HHS is slowly changing its rhetoric on the use of prescription opioids – edging away from crisis to finding positive trends. A new OIG report on opioid use in Medicare Part D emphasizes sustained positive trends in naloxone rescue and medication assisted treatment alternatives to opioid use disorder.
Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation
Here is what to expect from – and some free advice for – seven industry executives as they prepare for a hearing on drug pricing in the Senate Finance Committee.
Pharma’s Blame-The-Middleman Strategy Pays Off – For Now
Success of drug industry’s campaign to highlight role of 'middlemen' in the supply chain was never more clear than during President Trump’s Rose Garden drug pricing event. But what happens now that the attention is turned squarely back on manufacturers?